{"name":"Endo","slug":"endo","ticker":"NDOI","exchange":"NASDAQ","domain":"endo.com","description":"Endo International plc is a specialty pharmaceutical company focused on developing and commercializing branded and generic medicines. The company's portfolio includes a range of products in the pain management, urology, and gynecology therapeutic areas. Endo operates in the US and internationally, with a significant presence in the generic pharmaceutical market. As of 2023, Endo is a leading player in the specialty pharma and generics sector.","hq":"Malvern, PA","founded":0,"employees":"","ceo":"Blaise Coleman","sector":"Specialty Pharma / Generics","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$6.5B","metrics":{"revenue":2616907000,"revenueGrowth":-7.1,"grossMargin":0,"rdSpend":142472000,"netIncome":-685339000,"cash":6571856000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2013"},"revenueBreakdown":[],"timeline":[{"date":"1943-01-01","label":"Hycodan first approved","drug":"Hycodan","drugSlug":"methylhomatropine","type":"approval","sentiment":"positive"},{"date":"1950-01-01","label":"Aspirin first approved","drug":"Aspirin","drugSlug":"acetylsalicylic-acid","type":"approval","sentiment":"positive"},{"date":"1953-01-01","label":"Xyosted (Autoinjector) first approved","drug":"Xyosted (Autoinjector)","drugSlug":"testosterone-enantate","type":"approval","sentiment":"positive"},{"date":"1959-01-01","label":"Opana Er first approved","drug":"Opana Er","drugSlug":"oxymorphone","type":"approval","sentiment":"positive"},{"date":"1962-01-01","label":"Valpin first approved","drug":"Valpin","drugSlug":"anisotropine-methylbromide","type":"approval","sentiment":"positive"},{"date":"1962-01-01","label":"Valpin first approved","drug":"Valpin","drugSlug":"octatropine-methylbromide","type":"approval","sentiment":"positive"},{"date":"1968-01-01","label":"Gocovri first approved","drug":"Gocovri","drugSlug":"amantadine","type":"approval","sentiment":"positive"},{"date":"2001-01-01","label":"Frova first approved","drug":"Frova","drugSlug":"frovatriptan","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2025-06-01","label":"Vantas patent cliff ($100M at risk)","drug":"Vantas","type":"patent_expiry","sentiment":"negative"},{"date":"2026-06-01","label":"SuppreMol patent cliff ($50M at risk)","drug":"SuppreMol","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":13,"colorKey":"immunology","drugs":[{"name":"testosterone gel 2%","genericName":"testosterone gel 2%","slug":"testosterone-gel-2","indication":"Other","status":"marketed"},{"name":"Fortesta","genericName":"Fortesta","slug":"fortesta","indication":"Other","status":"marketed"},{"name":"Lidoderm","genericName":"Lidoderm","slug":"lidoderm","indication":"Other","status":"marketed"},{"name":"Testim","genericName":"Testim","slug":"testim","indication":"Other","status":"marketed"},{"name":"DHEA (0.25%)","genericName":"DHEA (0.25%)","slug":"dhea-0-25","indication":"Moderate to severe dyspareunia due to vaginal atrophy in postmenopausal women","status":"phase_3"},{"name":"DHEA (0.5%)","genericName":"DHEA (0.5%)","slug":"dhea-0-5","indication":"Moderate to severe dyspareunia due to menopause-related vaginal atrophy","status":"phase_3"},{"name":"DHEA and Acolbifene","genericName":"DHEA and Acolbifene","slug":"dhea-and-acolbifene","indication":"Moderate to severe vasomotor symptoms associated with menopause","status":"phase_3"},{"name":"EN3342","genericName":"EN3342","slug":"en3342","indication":"Other","status":"phase_1"},{"name":"Ertafolide","genericName":"Ertafolide","slug":"ertafolide","indication":"Other","status":"phase_2"},{"name":"Hycodan","genericName":"METHYLHOMATROPINE","slug":"methylhomatropine","indication":"Cough","status":"marketed"},{"name":"Prasterone (DHEA)","genericName":"Prasterone (DHEA)","slug":"prasterone-dhea","indication":"Moderate to severe dyspareunia due to genitourinary syndrome of menopause (GSM) in postmenopausal women","status":"phase_3"},{"name":"Valpin","genericName":"ANISOTROPINE METHYLBROMIDE","slug":"anisotropine-methylbromide","indication":"Gastric ulcer","status":"marketed"},{"name":"Valpin","genericName":"octatropine methylbromide","slug":"octatropine-methylbromide","indication":"Gastric ulcer","status":"marketed"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"Opana Er","genericName":"OXYMORPHONE","slug":"oxymorphone","indication":"Acute Pain Management","status":"marketed"},{"name":"DHEA (1.0%)","genericName":"DHEA (1.0%)","slug":"dhea-1-0","indication":"Moderate to severe dyspareunia (painful intercourse) due to menopause","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"neuroscience","drugs":[{"name":"99mTc-Etarfolatide","genericName":"99mTc-Etarfolatide","slug":"99mtc-etarfolatide","indication":"Ovarian cancer","status":"phase_1"},{"name":"Xyosted (Autoinjector)","genericName":"testosterone enantate","slug":"testosterone-enantate","indication":"Deficiency of testosterone biosynthesis","status":"marketed"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"respiratory","drugs":[{"name":"Frova","genericName":"FROVATRIPTAN","slug":"frovatriptan","indication":"Migraine","status":"marketed"},{"name":"Gocovri","genericName":"AMANTADINE","slug":"amantadine","indication":"Arteriosclerotic Parkinsonism","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Aspirin","genericName":"acetylsalicylic acid","slug":"acetylsalicylic-acid","indication":"Arthritic Pain","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"Aplisol","genericName":"TUBERCULIN","slug":"tuberculin","indication":"infection with Mycobacterium tuberculosis","status":"marketed"}]}],"pipeline":[{"name":"Aspirin","genericName":"acetylsalicylic acid","slug":"acetylsalicylic-acid","phase":"marketed","mechanism":"Orphenadrine citrate centrally acts on brain stem to selectively block facilitatory reticular functions.","indications":["Arthritic Pain","Backache","Common cold","Headache disorder","Influenza-like symptoms"],"catalyst":""},{"name":"testosterone gel 2%","genericName":"testosterone gel 2%","slug":"testosterone-gel-2","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Fortesta","genericName":"Fortesta","slug":"fortesta","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Lidoderm","genericName":"Lidoderm","slug":"lidoderm","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Opana Er","genericName":"OXYMORPHONE","slug":"oxymorphone","phase":"marketed","mechanism":"Mu-type opioid receptor","indications":["Acute Pain Management"],"catalyst":""},{"name":"Testim","genericName":"Testim","slug":"testim","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"99mTc-Etarfolatide","genericName":"99mTc-Etarfolatide","slug":"99mtc-etarfolatide","phase":"phase_1","mechanism":"binds to folate receptor beta","indications":["Ovarian cancer","Breast cancer"],"catalyst":""},{"name":"Aplisol","genericName":"TUBERCULIN","slug":"tuberculin","phase":"marketed","mechanism":"","indications":["infection with Mycobacterium tuberculosis","TB disease","M. tuberculosis infections","TB infection"],"catalyst":""},{"name":"DHEA (0.25%)","genericName":"DHEA (0.25%)","slug":"dhea-0-25","phase":"phase_3","mechanism":"DHEA (dehydroepiandrosterone) is a prohormone that is converted to estrogen and testosterone in peripheral tissues, restoring hormone levels in postmenopausal women.","indications":["Moderate to severe dyspareunia due to vaginal atrophy in postmenopausal women","Vaginal atrophy and related menopausal symptoms"],"catalyst":""},{"name":"DHEA (0.5%)","genericName":"DHEA (0.5%)","slug":"dhea-0-5","phase":"phase_3","mechanism":"DHEA (dehydroepiandrosterone) is a prohormone that is converted to testosterone and estrogen in peripheral tissues, restoring hormone levels in postmenopausal women.","indications":["Moderate to severe dyspareunia due to menopause-related vaginal atrophy","Vaginal atrophy and related menopausal symptoms"],"catalyst":""},{"name":"DHEA (1.0%)","genericName":"DHEA (1.0%)","slug":"dhea-1-0","phase":"phase_3","mechanism":"DHEA is a steroid hormone precursor that acts as a prohormone, being converted in peripheral tissues to testosterone and estrogen to restore hormonal balance.","indications":["Moderate to severe dyspareunia (painful intercourse) due to menopause","Vaginal atrophy and related menopausal symptoms"],"catalyst":""},{"name":"DHEA and Acolbifene","genericName":"DHEA and Acolbifene","slug":"dhea-and-acolbifene","phase":"phase_3","mechanism":"DHEA and acolbifene work together as a selective estrogen receptor modulator (SERM) combination to provide estrogen-like benefits in bone and vaginal tissue while minimizing systemic estrogen exposure.","indications":["Moderate to severe vasomotor symptoms associated with menopause","Vaginal atrophy and genitourinary syndrome of menopause"],"catalyst":""},{"name":"EN3342","genericName":"EN3342","slug":"en3342","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ertafolide","genericName":"Ertafolide","slug":"ertafolide","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Frova","genericName":"FROVATRIPTAN","slug":"frovatriptan","phase":"marketed","mechanism":"Frova works by binding to serotonin receptors in the brain to relieve migraine symptoms.","indications":["Migraine"],"catalyst":""},{"name":"Gocovri","genericName":"AMANTADINE","slug":"amantadine","phase":"marketed","mechanism":"Sigma non-opioid intracellular receptor 1","indications":["Arteriosclerotic Parkinsonism","Extrapyramidal disease","Influenza A Prevention","Influenza due to Influenza A virus","Parkinson's disease"],"catalyst":""},{"name":"Hycodan","genericName":"METHYLHOMATROPINE","slug":"methylhomatropine","phase":"marketed","mechanism":"Hycodan works by affecting the nervous system to reduce cough and relieve symptoms of irritable bowel syndrome and peptic ulcer.","indications":["Cough","Irritable bowel syndrome","Peptic ulcer"],"catalyst":""},{"name":"Prasterone (DHEA)","genericName":"Prasterone (DHEA)","slug":"prasterone-dhea","phase":"phase_3","mechanism":"Prasterone (DHEA) is a steroid hormone precursor that acts as a substrate for the synthesis of estrogen and androgen, restoring hormonal balance in postmenopausal women.","indications":["Moderate to severe dyspareunia due to genitourinary syndrome of menopause (GSM) in postmenopausal women","Vaginal atrophy and related menopausal symptoms"],"catalyst":""},{"name":"Valpin","genericName":"ANISOTROPINE METHYLBROMIDE","slug":"anisotropine-methylbromide","phase":"marketed","mechanism":"Muscarinic acetylcholine receptor M1","indications":["Gastric ulcer","Peptic ulcer"],"catalyst":""},{"name":"Valpin","genericName":"octatropine methylbromide","slug":"octatropine-methylbromide","phase":"marketed","mechanism":"Muscarinic acetylcholine receptor M1","indications":["Gastric ulcer","Peptic ulcer"],"catalyst":""},{"name":"Xyosted (Autoinjector)","genericName":"testosterone enantate","slug":"testosterone-enantate","phase":"marketed","mechanism":"Androgen receptor","indications":["Deficiency of testosterone biosynthesis","Delayed puberty","Hormone receptor positive malignant neoplasm of breast","Klinefelter's syndrome, XXY","LHRH Deficiency"],"catalyst":""}],"recentEvents":[{"date":"2023-02-27","type":"earnings","headline":"Endo International Reports Fourth Quarter and Full Year 2022 Financial Results","summary":"Endo International plc (NASDAQ: ENDP) today reported financial results for the fourth quarter and full year 2022.","drugName":"","sentiment":"neutral"},{"date":"2022-11-14","type":"deal","headline":"Endo International Announces Agreement to Sell U.S. Branded Prescription Opioid Business to Teva Pharmaceuticals","summary":"Endo International plc (NASDAQ: ENDP) today announced that it has entered into a definitive agreement to sell its U.S. branded prescription opioid business to Teva Pharmaceuticals.","drugName":"","sentiment":"neutral"},{"date":"2022-09-01","type":"regulatory","headline":"Endo International Receives FDA Approval for Generic Version of Lidoderm","summary":"Endo International plc (NASDAQ: ENDP) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its generic version of Lidoderm.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxONHBUNy15cGlZNHBUdkxfQUhEN1M1anlZRkxseVJfOGN4dFB1ZFh6WmJGNVhXMXRDVmRWWWhpTk5OS0hMT0RhWTJYME5JSHdUc2xjMVFiaE5mS29md3A0QlB1UHpvVHFtbVgtQmJFN0FxMTY1X25mSVQ4MmFGaDlJZ3ZEOWt3VEpiN3F3dEdsM2dSRUxuQjBXT1JxUVZZUjhK?oc=5","date":"2025-06-17","type":"pipeline","source":"Yahoo Finance","summary":"Endo Completes International Pharmaceuticals Business Divestiture - Yahoo Finance","headline":"Endo Completes International Pharmaceuticals Business Divestiture","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAJBVV95cUxPQUZxU29yMG13cVQyQnB2ZXZKVXd5a2J5WlBjNHM4WE03NnFjb3RzanJmT2htZ1A0bDdRcVZ6Z181R3l6ZUk0ME00OHFhUm1FU056dE1oTDl0N1BBWC1RSTBEYnhJazZRamd1OVkyakx4cDU0OEZOeFAzYUUzaVhtSFQ1aXBBUGhRNEdxay1MXzJlczlUeGY3UkZaUlBmRnBEaWhIM2NsckNBb0ljSGdQTHl2X21OR3Z3MVVfanBVSzVKdWJJQXBxRk56aVN4MUNqLWZueDZHaGk5V0c2cnc0RnhZWm9jb3JOV3dORTJqWVFVZmd2WDFBLXBNSWRBd3Qx?oc=5","date":"2025-06-13","type":"regulatory","source":"PR Newswire","summary":"Mallinckrodt and Endo Shareholders Approve Combination to Create a Global, Scaled, Diversified Pharmaceuticals Leader - PR Newswire","headline":"Mallinckrodt and Endo Shareholders Approve Combination to Create a Global, Scaled, Diversified Pharmaceuticals Leader","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxQZUtRS1BVOU9jZ3YzTElzYmNfVmZzaWRDUzhlcVliLTZfRUhNVjdvYTVIdGx4NEZGVWVEWktqYnZ6aXk0b185amxGT3U4NmNnbVJXcnFxNlgxZTlwTDFqeWk3UDkyR0pzaVNfZzdsS0ZCRU5OUTJISHNBbFl6cHZmckwtWkdXSHhOc3k0cDhnc0VNWlRGbWxWUWdPODc4OUJPQXZfS0gtMjlIeWNCY3BTSks2blJrUmRIX05iVVpKYkNHclcw?oc=5","date":"2025-05-13","type":"deal","source":"PR Newswire","summary":"Mallinckrodt and Endo Announce Significant Progress in Proposed Merger - PR Newswire","headline":"Mallinckrodt and Endo Announce Significant Progress in Proposed Merger","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1Fai1Ta0tDeGY0UzdNcjZsMkZQNjFzdko3ckxMQVJoN0VyNnBHNGxvVHo0aGtEQXRtUlRvM29VaUItS2xpOEt2c3ZpM0k3RVRhMDF3?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"NDOI Stock Price, News & Analysis - Stock Titan","headline":"NDOI Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPQjdZTFZvcnIzRmgwdktkRENFUkVrOTFTWWdORVBUWG1fMEM0TUdYWVZJUi0xSWllMmRXMjFyZ055eHFhdHNGUElydHV5N3B2ejN5X2VmSzdHSHVCTFk3M1R3b01WN1BEaERfU0Z4QXB3YUdPVG9waGlnNjMzcDdQYnNFQ05aNVFqLXFhU191NmgxeXotaU9vd2pNZ29Ea3VIUjVj?oc=5","date":"2025-03-26","type":"deal","source":"Akin","summary":"Mallinckrodt and Endo Announce Merger, Possible Spin - Akin","headline":"Mallinckrodt and Endo Announce Merger, Possible Spin","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE80SnF5VDZyVG56bUoxSFBYUnZvYWhkZVN5U0o0MU4xMWpCSkI1U3RQUzZSV25lLTJ0M0EzSGZWMWZ5aFhFSGt2WHVuUzAwa20yR3JWWnhrWWxaajRZNG4wZy03SEpZYTJwSGRrVUV1bEdVdXQwSlE2MWhvNDI1VUU?oc=5","date":"2025-03-13","type":"deal","source":"MedCity News","summary":"Pharma Firms Mallinckrodt and Endo Agree to Merge in $6.7B Cash and Stock Deal - MedCity News","headline":"Pharma Firms Mallinckrodt and Endo Agree to Merge in $6.7B Cash and Stock Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQZkcwdVVfTExqc1dEWVI1XzdYd3BmMUtucmhGMnY4dGJyOVMtNkJEWmJLN00tek1qckRIc2FsWDNJR0czWEtucHFHbEtFUFVkS1phZUlnbE44ZlB6RF9hTURWakpzZTVmSHlpTmltYXdhOThpa1N4TEJDQ21EQ1lmMzR3aWdTLVltU1Z3M3lLcHBHQ2pkOVZfUHprQTdzeWs4Y2N6SkdB?oc=5","date":"2025-03-13","type":"deal","source":"Fierce Pharma","summary":"Mallinckrodt, Endo look to carve out brighter future through $6.7B merger - Fierce Pharma","headline":"Mallinckrodt, Endo look to carve out brighter future through $6.7B merger","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE5DN2Y3dElzTWEyM2JFV1h0ekdfbjFWd0NQc1VVbmh0VTkxYjJjZURkN252Y0wzT1luYk1YX09sVTlJR1BoenhvZmpQc0NJcnVxVUZkU2VxSnZqOVdhU1pucmg4TjRVajVwWXRvV2ZoOWpBbGNQWWtNaWhYZw?oc=5","date":"2025-03-13","type":"pipeline","source":"The Pharma Letter","summary":"Troubled Mallinckrodt and Endo to merge - The Pharma Letter","headline":"Troubled Mallinckrodt and Endo to merge","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxOaFUtYXNpcWtpVlVScUhMdHBvOWVDZGNJU2lOYV8yUVM1Q1c2XzdmOHRreVBjRmNqTXZzWmdrRkZITXR3TlY0VEVfN2s1TFJzbWljTUgwODdjYm54N2RMUm5pdUVqSjZrVS0xS1pYSkE3aW5WT29qTFBURmRCejJ5ZjZQQjTSAYoBQVVfeXFMT0xXTjNMdWZpUmdlUldwZDRJQmdaVHZIRWkyS3duWDRvVDg5c1ludTRSRUpvdTB1UDZHbjM3Z1ZEMVd0c2NSWnQtWmI1OXZpTWdTQVlVS202LXh5clZlVFZjUlJ2S2h3MERUTkdTTXF4TjdXYm80UHQtUnhYcEMtYTFWT3Y0QVQ5ZHln?oc=5","date":"2025-03-13","type":"deal","source":"cnbc.com","summary":"Drugmakers Mallinckrodt and Endo to merge in nearly $7 billion deal - cnbc.com","headline":"Drugmakers Mallinckrodt and Endo to merge in nearly $7 billion deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE1lcGc1VjNlSURnSmEzSkVBcGltbC0wbWNIc3RFamNEdWNiRkkzSTZTcTlUaTlNZFIzc1pPTmVzdmVES0I0M1FRQ1BCTnpCeWFOSXl0QWY4QmdMNGZxZk9jLVgyUW51NWZtcXJ1eHF4OWNrX1JNZzdFeA?oc=5","date":"2025-03-13","type":"pipeline","source":"citybiz","summary":"Mallinckrodt and Endo to Merge - citybiz","headline":"Mallinckrodt and Endo to Merge","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxPTGlRUzhMTFdLdGpyMnR4WTJVak9BcXVFRDNBS0tBOGhVZXpPUFdwT2s1Vm9wNGNaLTh3MXFkTlRIRklwNTJjVlBEeUszTnhRdmNxcWpMSHZ1cWJiLURzZnJVdWFxTWhTb0tRdTdwYUhyekVpSEhqXy1CVEI5WUxXcS1icF96QlVibWFhTUtBYndEa3h3cHBLcU1OOHNha0ptdU9PZkJSalhnQkdQVGtXNmdZOWNVVlNESHJlVXBBWGtJUjJlamg4?oc=5","date":"2025-03-13","type":"deal","source":"Reuters","summary":"Drugmakers Mallinckrodt and Endo get a bump from tariffs in $6.7 billion merger - Reuters","headline":"Drugmakers Mallinckrodt and Endo get a bump from tariffs in $6.7 billion merger","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxQaGxCbGN1c3BXTlBNdWlCMXhQNkJNbUljZ2NNU0Zoc1hkSlhpOUllRTBpUXU3RjladS1LUE5aOVZEMFR5NkEyRUYwbm5xU1RtOHl0Z0ZrNG1zTy1HOUdJOXQ3QXZKSVpIQjlMek1CbEFwcVFvS2s2c2hfUTgwRjY1NHJ0Y0V1Z0NodmtZeWthS1BNTVlzTDVZaTJ1V1BvQnRtcFVTODRJYXNoUzVmVkk0ekR3MnpnbkJvekxUOUd2UWtEZnpxMVRGZTFENVdXVFRj?oc=5","date":"2025-03-12","type":"pipeline","source":"Reuters","summary":"Drugmakers Mallinckrodt, Endo in talks to merge, source says - Reuters","headline":"Drugmakers Mallinckrodt, Endo in talks to merge, source says","sentiment":"neutral"},{"date":"2015-02-11","type":"earnings","source":"SEC EDGAR","summary":"SC 13G filed with SEC","headline":"SC 13G Filing","sentiment":"neutral"}],"patents":[{"drugName":"Vantas","drugSlug":"histrelin-implant","patentNumber":"","type":"Patent Cliff","expiryDate":"2025-06-01","territory":"US","annualRevenue":100000000},{"drugName":"SuppreMol","drugSlug":"sulindac","patentNumber":"","type":"Patent Cliff","expiryDate":"2026-06-01","territory":"US","annualRevenue":50000000}],"drugCount":21,"phaseCounts":{"marketed":13,"phase_1":2,"phase_3":5,"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Pfizer","Johnson & Johnson","Allergan"],"therapeuticFocus":["Pain Management","Urology","Gynecology"],"financials":{"source":"sec_edgar","revenue":2616907000,"revenuePeriod":"2013-12-31","revenueHistory":[{"value":2616907000,"period":"2013-12-31"},{"value":2815736000,"period":"2012-12-31"},{"value":3027363000,"period":"2012-12-31"},{"value":2730121000,"period":"2011-12-31"},{"value":2524920000,"period":"2011-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":142472000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-685339000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":6571856000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}